180 related articles for article (PubMed ID: 36837874)
1. Vitamin D and Bone Metabolism in Adult Patients with Neurofibromatosis Type 1.
Modica R; Altieri B; D'Aniello F; Benevento E; Cannavale G; Minotta R; Liccardi A; Colao A; Faggiano A
Metabolites; 2023 Feb; 13(2):. PubMed ID: 36837874
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density, vitamin D and osseous metabolism indices in neurofibromatosis type 1: A systematic review and meta-analysis.
Kaspiris A; Vasiliadis E; Iliopoulos ID; Panagopoulos F; Melissaridou D; Lianou I; Ntourantonis D; Savvidou OD; Papadimitriou E; Pneumaticos SG
Bone; 2024 Mar; 180():116992. PubMed ID: 38141750
[TBL] [Abstract][Full Text] [Related]
3. Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group.
Santos A; Geller M; Mezitis S; Rubenstein AE; Oliveira L; Medeiros Lima DJ; Suchmacher Neto M; Nigri R; Cunha KGS; Takirambudde S; Gonçalves Ribeiro M
Clin Pathol; 2020; 13():2632010X20928930. PubMed ID: 35156025
[TBL] [Abstract][Full Text] [Related]
4. High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1.
Seitz S; Schnabel C; Busse B; Schmidt HU; Beil FT; Friedrich RE; Schinke T; Mautner VF; Amling M
Osteoporos Int; 2010 Jan; 21(1):119-27. PubMed ID: 19415373
[TBL] [Abstract][Full Text] [Related]
5. Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1).
Tucker T; Schnabel C; Hartmann M; Friedrich RE; Frieling I; Kruse HP; Mautner VF; Friedman JM
J Med Genet; 2009 Apr; 46(4):259-65. PubMed ID: 19066167
[TBL] [Abstract][Full Text] [Related]
6. Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity.
Ferrara UP; Tortora C; Rosano C; Assunto A; Rossi A; Pagano S; Falco M; Simeoli C; Ferrigno R; D'Amico A; Di Salvio D; Cangemi G; Pivonello R; Strisciuglio P; Melis D
Sci Rep; 2022 Mar; 12(1):4368. PubMed ID: 35288591
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease).
Petramala L; Giustini S; Zinnamosca L; Marinelli C; Colangelo L; Cilenti G; Formicuccia MC; D'Erasmo E; Calvieri S; Letizia C
Arch Dermatol Res; 2012 May; 304(4):325-31. PubMed ID: 22120694
[TBL] [Abstract][Full Text] [Related]
8. Bone Status According to Neurofibromatosis Type 1 Phenotype: A Descriptive Study of 60 Women in France.
Jalabert M; Ferkal S; Souberbielle JC; Sbidian E; Mageau A; Eymard F; Le Corvoisier P; Allanore L; Chevalier X; Wolkenstein P; Guignard S
Calcif Tissue Int; 2021 Jun; 108(6):738-745. PubMed ID: 33558959
[TBL] [Abstract][Full Text] [Related]
9. Effect of vitamin D3 treatment on bone density in neurofibromatosis 1 patients: a retrospective clinical study.
Schnabel C; Jett K; Friedman JM; Frieling I; Kruse HP; Mautner V
Joint Bone Spine; 2013 May; 80(3):315-9. PubMed ID: 23021159
[TBL] [Abstract][Full Text] [Related]
10. Trabecular Bone Score (TBS) and Bone Metabolism in Patients Affected with Type 1 Neurofibromatosis (NF1).
Filopanti M; Verga U; Ulivieri FM; Giavoli C; Rodari G; Arosio M; Natacci F; Spada A
Calcif Tissue Int; 2019 Feb; 104(2):207-213. PubMed ID: 30421324
[TBL] [Abstract][Full Text] [Related]
11. Differences of 25-hydroxyvitamin D3 concentrations in children and adults with neurofibromatosis type 1.
Schnabel C; Dahm S; Streichert T; Thierfelder W; Kluwe L; Mautner VF
Clin Biochem; 2014 May; 47(7-8):560-3. PubMed ID: 24613576
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1.
Lammert M; Friedman JM; Roth HJ; Friedrich RE; Kluwe L; Atkins D; Schooler T; Mautner VF
J Med Genet; 2006 Oct; 43(10):810-3. PubMed ID: 16571643
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density and bone metabolic markers' status in children with neurofibromatosis type 1.
Poyrazoğlu HG; Baş VN; Arslan A; Bastug F; Canpolat M; Per H; Gümüs H; Kumandas S
J Pediatr Endocrinol Metab; 2017 Feb; 30(2):175-180. PubMed ID: 28125404
[TBL] [Abstract][Full Text] [Related]
14. Bone densitometry measurements in children with neurofibromatosis Type 1 using quantitative computed tomography.
Tezol O; Balcı Y; Alakaya M; Gundogan B; Cıtak EC
Singapore Med J; 2022 Sep; 63(9):520-526. PubMed ID: 34005845
[TBL] [Abstract][Full Text] [Related]
15. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body.
Kuorilehto T; Pöyhönen M; Bloigu R; Heikkinen J; Väänänen K; Peltonen J
Osteoporos Int; 2005 Aug; 16(8):928-36. PubMed ID: 15551055
[TBL] [Abstract][Full Text] [Related]
16. The generalized bone phenotype in children with neurofibromatosis 1: a sibling matched case-control study.
Armstrong L; Jett K; Birch P; Kendler DL; McKay H; Tsang E; Stevenson DA; Hanley DA; Egeli D; Burrows M; Friedman JM
Am J Med Genet A; 2013 Jul; 161A(7):1654-61. PubMed ID: 23713011
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D receptor expression and serum 25(OH)D concentration inversely associates with burden of neurofibromas.
Kluwe L; Hagel C; Friedrich RE; Schnabel C; Schön G; Mautner V
Eur J Cancer Prev; 2019 May; 28(3):220-224. PubMed ID: 30299316
[TBL] [Abstract][Full Text] [Related]
18. Decreased bone mineral density in Costello syndrome.
Leoni C; Stevenson DA; Martini L; De Sanctis R; Mascolo G; Pantaleoni F; De Santis S; La Torraca I; Persichilli S; Caradonna P; Tartaglia M; Zampino G
Mol Genet Metab; 2014 Jan; 111(1):41-5. PubMed ID: 24246682
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density of the spine and femur in healthy Saudi females: relation to vitamin D status, pregnancy, and lactation.
Ghannam NN; Hammami MM; Bakheet SM; Khan BA
Calcif Tissue Int; 1999 Jul; 65(1):23-8. PubMed ID: 10369729
[TBL] [Abstract][Full Text] [Related]
20. Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women.
Kharroubi A; Saba E; Smoom R; Bader K; Darwish H
Arch Osteoporos; 2017 Dec; 12(1):13. PubMed ID: 28124221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
